本帖最后由 老马 于 2012-1-13 21:20 编辑
; @. p0 r, ?( n% V& M! c
# Y% U' \; X# j爱必妥和阿瓦斯丁的比较; q7 y# a( H a9 J! p- v0 ~3 | g* b2 y- ]
* M W2 k4 A6 K! k. \# }8 U" k& ^http://cancergrace.org/lung/2008/08/30/bms099-os-neg/! I& L/ p% B3 F
" W* d. a) A, C. F) ~- z& @
% Y G; q) A: E+ }1 y0 E# n5 i
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
# ?* c3 j( `& a6 x& Q==================================================
% K5 K* |, S! E# k. KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( W6 T0 ]( z8 U# |
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.0 S1 }# s0 ^, w1 r) W/ [; E6 t) U4 @
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.; N$ c2 P0 A/ ^ S! U& N
|
显身卡
